SS

Sheela Sunil Nayak

Active Director Director DIN 09558109
DIN 09558109 First appointment Apr 2022
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2022
Shareholding value •••• Premium profile

About Sheela Sunil Nayak

Data last updated:

Sheela Sunil Nayak is a Director at Sc Pharmachem Private Limited (since 2022). Sc Pharmachem Private Limited reported revenue of ₹32.36 Cr (FY 2025).

DIN 09558109
Primary Designation Director
First Appointment 01 Apr 2022
Oldest Company Age 4 yrs
Largest company Sc Pharmachem Private Limited · ₹32.36 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Sc Pharmachem Private Limited U59131MH2022PTC379760
Director01 Apr 20222022₹32.36 Cr (FY 2025)Active

Board colleagues of Sheela Sunil Nayak

Directorship timeline

Open interactive timeline →
Sc Pharmachem Private Limited
Premium access

Shareholding and investment profile for Sheela Sunil Nayak

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sheela Sunil Nayak

Sheela Sunil Nayak currently holds 1 directorship: Sc Pharmachem Private Limited (Director, since 01 Apr 2022, revenue ₹32.36 Cr (FY 2025)).

Sheela Sunil Nayak was first appointed on 01 Apr 2022 as Director at Sc Pharmachem Private Limited.

The current boards of Sheela Sunil Nayak's companies include Abhishek Sunil Nayak (Sc Pharmachem Private Limited), Nikita Abhishek Nayak (Sc Pharmachem Private Limited), Sunil Vishwanath Nayak (Sc Pharmachem Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available